India Globalization Capital Inc - Asset Resilience Ratio

Latest as of September 2025: 11.60%

India Globalization Capital Inc (IGC) has an Asset Resilience Ratio of 11.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of India Globalization Capital Inc for a breakdown of total debt and financial obligations.

Liquid Assets

$1.13 Million
Cash + Short-term Investments

Total Assets

$9.74 Million
All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how India Globalization Capital Inc's Asset Resilience Ratio has changed over time. See India Globalization Capital Inc (IGC) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down India Globalization Capital Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see India Globalization Capital Inc market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $1.10 Million 11.34%
Short-term Investments $25.00K 0.26%
Total Liquid Assets $1.13 Million 11.60%

Asset Resilience Insights

  • Moderate Liquidity: India Globalization Capital Inc has 11.60% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

India Globalization Capital Inc Industry Peers by Asset Resilience Ratio

Compare India Globalization Capital Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
Biotechnology 63.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 43.36%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bio-Thera Solutions Ltd
SHG:688177
Biotechnology 4.09%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Gubra A/S
CO:GUBRA
Biotechnology 79.61%

Annual Asset Resilience Ratio for India Globalization Capital Inc (2006–2025)

The table below shows the annual Asset Resilience Ratio data for India Globalization Capital Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 4.63% $405.00K $8.75 Million -7.47pp
2024-03-31 12.10% $1.20 Million $9.90 Million -7.40pp
2023-03-31 19.50% $3.35 Million $17.18 Million -19.48pp
2022-03-31 38.98% $10.46 Million $26.83 Million -1.80pp
2021-03-31 40.78% $14.63 Million $35.87 Million -1.79pp
2020-03-31 42.57% $12.34 Million $28.98 Million -34.00pp
2019-03-31 76.57% $26.39 Million $34.47 Million +59.93pp
2018-03-31 16.65% $1.81 Million $10.85 Million -4.78pp
2017-03-31 21.43% $2.42 Million $11.28 Million +21.34pp
2016-03-31 0.09% $17.17K $18.86 Million -0.15pp
2015-03-31 0.24% $49.54K $20.33 Million +0.04pp
2014-03-31 0.20% $35.69K $17.73 Million +0.11pp
2013-03-31 0.09% $16.85K $19.25 Million --
2012-03-31 0.00% $0.00 $25.26 Million --
2008-03-31 4.44% $3.00 Million $67.63 Million -89.08pp
2007-03-31 93.52% $66.10 Million $70.69 Million -6.33pp
2006-03-31 99.84% $65.83 Million $65.93 Million --
pp = percentage points

About India Globalization Capital Inc

NYSE MKT:IGC USA Biotechnology
Market Cap
$27.46 Million
Market Cap Rank
#24173 Global
#5079 in USA
Share Price
$0.29
Change (1 day)
+2.81%
52-Week Range
$0.25 - $0.47
All Time High
$13.00
About

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more